CagriSema: semaglutide plus an amylin copy, in trials
CagriSema is an experimental two-hormone weight-loss shot still in trials and not approved anywhere, including India. Early results look strong but came in below what the maker hoped, so it is years from reach.
You may have heard news about a new weight-loss shot called CagriSema. It sounds exciting because it mixes two hunger-fighting signals in one pen. But here is the honest truth: CagriSema is still being tested in trials. It is NOT approved, NOT sold, and NOT available in India or anywhere else. This short read explains what it is, what the trials really showed, and why you should not try to buy it.
What CagriSema actually is
CagriSema is a fixed-dose combination shot made by Novo Nordisk. It blends two medicines in one weekly injection: cagrilintide 2.4 mg and semaglutide 2.4 mg. Semaglutide is the GLP-1 medicine inside Ozempic and Wegovy. Cagrilintide is a long-acting copy of amylin. Amylin is a second hormone made by the pancreas alongside insulin. It makes you feel full, slows food leaving the stomach, and lowers after-meal sugar spikes. The idea is simple: GLP-1 plus amylin together may cut hunger more than GLP-1 alone.
REDEFINE-1 trial results (people WITHOUT diabetes)
CagriSema is the new best weight-loss medicine and you can get it now.
mostly falseMostly false. The 22.7% loss in REDEFINE-1 is among the best seen in any Phase 3 trial, and it beat both single hormones. But CagriSema is NOT approved, NOT sold, and NOT available in India or anywhere. Novo Nordisk plans to file for first approval around Q1 2026. Even if approved later, it would reach Indian pharmacies much later. Do not buy anything sold online as 'CagriSema' — those are fake.
The honest setback: results came in LOWER than hoped
Here is the part some news hides. CagriSema had two disappointing moments. In December 2024, REDEFINE-1 showed 22.7% weight loss. That sounds great, but Novo Nordisk had publicly aimed for 25%, and only 57% of people reached the top dose. Its shares fell about 20% in one day. In March 2025, REDEFINE-2 (in people WITH type 2 diabetes) showed 13.7% weight loss, below the 'high-teens' analysts expected, and shares fell again. So the honest story is: promising concept, but mixed recent news, and the medicine is not better than Lilly's tirzepatide by a clear margin. This is normal in science, but it means you should not believe the hype that CagriSema is a miracle.
What you can actually do today
The bottom line
CagriSema is a clever idea: GLP-1 plus an amylin copy in one weekly shot. Trials show strong weight loss, but results came in below the maker's hopes, and it is NOT approved or available in India. Do not seek it or buy it. If you want medicine help for weight loss, talk to your doctor about what is approved today.